Todd J Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Todd J Johnson has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Betsy C. Herold
Division of Pediatric Infectious Diseases at the Children’s Hospital at Montefiore and the Albert Einstein College Medicine
1 shared publication - James M. Smith
Natl Ctr HIV, CDCP, Div HIV Prevent, Lab Branch, Atlanta, GA USA
1 shared publication - Karen W. Buckheit
ImQuest BioSciences, 7340 Executive Way Suite R, Frederick, MD 21704, USA
1 shared publication - Michael S. Kay
Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, USA
1 shared publication - Patrick Franklin Kiser
Department of Biomedical Engineering, Northwestern University, Evanston, Illinois, USA
1 shared publication - Pedro M. M. Mesquita
Department of Pediatrics, Albert Einstein College of Medicine, Bronx, New York, USA
1 shared publication
Latest Publications
- Open Access
- 24 October 2013
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 113
Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties
The limited success of recent HIV topical pre-exposure prophylaxis clinical trials highlights the need for more predictive models of drug efficacy that better simulate what may happen during sexual exposure. To address this gap, we developed complementary in vitro models to evaluate the ability of drugs to retain anti-HIV activity if cells were washed with seminal plasma (simulating what may happen following exposure to ejaculate), and to protect drug-naive T cells (representing newly recruited immune cells) co-cultured with explants that had been pretreated with drug. We focused on tenofovir disoproxil fumarate (TDF), the non-nucleoside reverse transcriptase inhibitors dapivirine (DPV) and IQP-0528, and the entry inhibitors maraviroc (MVC) and the D-peptide chol-PIE-12 trimer (PIE12). Studies were extended to macaques and the ability of cervical biopsies obtained from animals treated with an intravaginal ring formulation of IQP-0528 to protect ex vivo co-cultured T cells was determined. The antiviral activity of cervicovaginal lavage samples against a primary Clade C isolate was also measured and correlated with drug levels.
- 24 October 2013
- Published by Springer Nature in Retrovirology
- Vol. 10 (1) , 113
Open AccessNovel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties
The limited success of recent HIV topical pre-exposure prophylaxis clinical trials highlights the need for more predictive models of drug efficacy that better simulate what may happen during sexual exposure. To address this gap, we developed complementary in vitro models to evaluate the ability of drugs to retain anti-HIV activity if cells were washed with seminal plasma (simulating what may happen following exposure to ejaculate), and to protect drug-naive T cells (representing newly recruited immune cells) co-cultured with explants that had been pretreated with drug. We focused on tenofovir disoproxil fumarate (TDF), the non-nucleoside reverse transcriptase inhibitors dapivirine (DPV) and IQP-0528, and the entry inhibitors maraviroc (MVC) and the D-peptide chol-PIE-12 trimer (PIE12). Studies were extended to macaques and the ability of cervical biopsies obtained from animals treated with an intravaginal ring formulation of IQP-0528 to protect ex vivo co-cultured T cells was determined. The antiviral activity of cervicovaginal lavage samples against a primary Clade C isolate was also measured and correlated with drug levels.